Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | NPY4R | P50391 | 9/20 | 0.40 |
| ▸ | NPY1R | P25929 | 5/20 | 0.40 |
| ▸ | NPY2R | P49146 | 4/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | RRM1 | P23921 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578552 | 1.00 | GNAI3 (0.46) | GNAI3GNAO1GNAI1DPP7DPP8 | |
| SCHEMBL8697740 | 1.00 | GNAI3 (0.46) | GNAI3GNAO1GNAI1DPP7DPP8 | |
| SCHEMBL4586178 | 1.00 | GNAI3 (0.46) | GNAI3GNAO1GNAI1DPP7DPP8 | |
| SCHEMBL2183420 | 0.93 | NPY4R (0.41) | GNAI3GNAO1GNAI1DPP7DPP8 | |
| SCHEMBL1521188 | 0.93 | NPY4R (0.41) | GNAI3GNAO1GNAI1DPP7DPP8 | |
| SCHEMBL1521191 | 0.93 | NPY4R (0.41) | GNAI3GNAO1GNAI1DPP7DPP8 | |
| SCHEMBL15263460 | 0.88 | NPY4R (0.48) | GNAI3GNAO1GNAI1NPY4RNPY1R | |
| SCHEMBL3043193 | 0.88 | NPY4R (0.43) | GNAI3GNAO1GNAI1NPY4RNPY1R | |
| SCHEMBL2185394 | 0.87 | NPY4R (0.58) | GNAI3GNAO1GNAI1NPY4RNPY1R | |
| SCHEMBL2195938 | 0.87 | NPY4R (0.49) | GNAI3GNAO1GNAI1DPP7NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5811401-A | Advanced glycosylation endproducts and methods of use therefor | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-09-22 | — | — | US | claimed |
| US-4861755-A | Peptides with vasorelaxant, natriuretic and diuretic effects a process for their preparation, agents containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-29 | — | — | US | claimed |
| EP-4362904-A1 | COSMETIC, NON-THERAPEUTIC USES OF PEPTIDES | Lubrizol Advanced Materials, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-116801910-A | Means and methods for producing antibody-linker conjugates | 阿拉里斯生物技术股份公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-4232095-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | Araris Biotech AG (CH) | 2023-08-30 | — | — | EP | disclosed |
| US-20230263904-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2023-08-24 | — | — | US | disclosed |
| WO-2023275811-A1 | COSMETIC, NON-THERAPEUTIC USES OF PEPTIDES | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022084560-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | ARARIS BIOTECH AG (CH) | 2022-04-28 | — | — | WO | disclosed |
| EP-3921328-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | Lubrizol Advanced Materials, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3833674-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | Lubrizol Advanced Materials, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020161683-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| CN-1674928-A | Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases | AMGEN INC (US) | 2005-09-28 | — | — | CN | disclosed |
| EP-1239873-B1 | USE OF FIBRINOLYTIC METALLOPROTEINASES FOR THE THERAPEUTIC TREATMENT OF A BLOOD CLOT | AMGEN INC (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1531856-A1 | METHOD FOR TREATMENT OF INDWELLING CATHETER OCCLUSION USING FIBRINOLYTIC METALLOPROTEINASES | Amgen Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004000348-A1 | METHOD FOR TREATMENT OF INDWELLING CATHETER OCCLUSION USING FIBRINOLYTIC METALLOPROTEINASES | AMGEN INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20020197246-A1 | Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases | AMGEN INC. | 2002-12-26 | — | — | US | disclosed |
| US-6455269-B1 | ADMINISTERING BY CATHETER DELIVERY A FIBRINOLYTIC METALLOPROTEINASE THAT COMPLEXES WITH ALPHA-TWO MICROGLOBULIN; TREATMENT OF BLOOD CLOTS AND CARDIOVASCULAR DISORDERS | AMGEN, INC. | 2002-09-24 | — | — | US | disclosed |
| EP-1239873-A2 | USE OF FIBRINOLYTIC METALLOPROTEINASES FOR THE THERAPEUTIC TREATMENT OF A BLOOD CLOT | Amgen Inc., (US) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001043765-A2 | METHOD FOR LOCALIZED ADMINISTRATION OF FIBRINOLYTIC METALLOPROTEINASES | AMGEN INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| US-4861755-A | Peptides with vasorelaxant, natriuretic and diuretic effects a process for their preparation, agents containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263904-A1 | MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES | TGM1, TGM3, TGM2 | GNAI3 1859/4885GNAO1 3873/4885GNAI1 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.